Nevertheless, the data that have been collected and analyzed in this review provide a strong indication of the ability of GLP-1 RAs, especially liraglutide and semaglutide, to simultaneously treat NASH and inhibit the progression of atherosclerosis, thus protecting against atherogenic cardiovascular events. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.